Skip to content

Apimeds Pharmaceuticals US, Inc.

APUS

CIK 0001894525

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$39.91M
−331.7% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.71
−205.6% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$8.98M
Q1 May 2026
Cash
$979.53K
Q1 May 2026
Total Debt
$20K
Q1 May 2026
Shares Outstanding
15.09M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings